EVALUATION OF MEMBRANOUS NEPHROPATHY DIAGNOSTIC AND MANAGEMENT APPROACH

被引:0
|
作者
Bokheder, Mojtaba Ali [1 ]
Asiri, Bander Bin Saleh Alsalmy [2 ]
Alsarah, Aouss Khalid Asad [2 ]
Alshahrani, Nawaf Abdullah [2 ]
Tarish, Saad Mohammed Al [2 ]
Harakati, Amal Maher [3 ]
Almuntashiri, Ibtisam Aziz A. [3 ]
Alamir, Feras Ahmed [4 ]
Alshmri, Shumukh Mohammed [5 ]
Alkhaldi, Ghadah Nashmi [6 ]
机构
[1] Omran Gen Hosp, Dept Med, Al Hasa, Saudi Arabia
[2] King Khalid Univ, Fac Med, Abha, Saudi Arabia
[3] King Abdulaziz Univ, Fac Med, Jeddah, Saudi Arabia
[4] Warsaw Med Univ, Fac Med, Warsaw, Poland
[5] Gurayat Gen Hosp, Dept Intens Care, Gurayat, Saudi Arabia
[6] Secur Forces Hosp, Dept Internal Med, Dammam, Saudi Arabia
来源
PHARMACOPHORE | 2021年 / 12卷 / 04期
关键词
Membranous nephropathy; Phospholipase A2 receptor; Systemic lupus erythematosus; Immunohistology; RECEPTOR ANTIBODY; HEYMANN NEPHRITIS; GLOMERULONEPHRITIS; THERAPY; DISEASE; IMMUNOPATHOGENESIS; PATHOMECHANISMS; COMPLEX; ANTIGEN;
D O I
10.51847/qixenY6Ym6
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Membranous nephropathy is one of the most common causes of nondiabetic adults' nephrotic syndrome. It accounts for up to 30% of nephrotic syndrome cases in Caucasian adults. It can manifest as a primary or secondary disease, but primary is considered more common. The disease has a waxing and waning clinical course and indolent progress, and immunosuppressive treatment is deemed the mainstay therapy for promoting remission. Although there has been advancement in understanding the pathogenesis of this disease, it still requires further research. We aimed to review the literature to promote the understanding of membranous nephropathy. We reviewed the literature for membranous nephropathy; pathogenesis, etiology, clinical presentation, diagnosis, and treatment. Articles were chosen from the PubMed database, and selected studies were subjected to a thorough review. Membranous nephropathy is one of the most common causes of nephrotic syndrome in nondiabetic adults. The clinical course of this disease is waxing and waning and has indolent progression. Despite the improvement in diagnostic approaches and treatment options, it remains an active field for diagnostic and pharmacological research. Copyright (C) 2013 - All Rights Reserved - Pharmacophore
引用
收藏
页码:73 / 78
页数:6
相关论文
共 50 条
  • [1] Updated diagnostic and therapeutic management for membranous nephropathy
    Caravaca-Fontan, Fernando
    Yandian, Federico
    Fervenza, Fernando C.
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2025, 34 (01): : 23 - 32
  • [2] Management of membranous nephropathy
    Cattran, D
    NEPHROLOGY, 2000, 5 (04) : 209 - 213
  • [3] Membranous Nephropathy: Updates on Management
    Bharati, Joyita
    Waguespack, Dia Rose
    Beck, Laurence H.
    ADVANCES IN KIDNEY DISEASE AND HEALTH, 2024, 31 (04): : 299 - 308
  • [4] Management of patients with membranous nephropathy
    Hofstra, Julia M.
    Wetzels, Jack F. M.
    NEPHROLOGY DIALYSIS TRANSPLANTATION, 2012, 27 (01) : 6 - 9
  • [5] Management of idiopathic membranous nephropathy
    Ponticelli, Claudio
    Passerini, Patrizia
    EXPERT OPINION ON PHARMACOTHERAPY, 2010, 11 (13) : 2163 - 2175
  • [6] Management of Membranous Nephropathy in Asia
    Xu, Jing
    Hu, Xiaofan
    Xie, Jingyuan
    Chen, Nan
    KIDNEY DISEASES, 2015, 1 (02) : 119 - 125
  • [7] Pharmacological management of membranous nephropathy
    Kincaid-Smith, P
    CURRENT OPINION IN NEPHROLOGY AND HYPERTENSION, 2002, 11 (02): : 149 - 154
  • [8] Advances in the Management of Primary Membranous Nephropathy and Rituximab-Refractory Membranous Nephropathy
    Teisseyre, Maxime
    Cremoni, Marion
    Boyer-Suavet, Sonia
    Ruetsch, Caroline
    Graca, Daisy
    Esnault, Vincent L. M.
    Brglez, Vesna
    Seitz-Polski, Barbara
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [9] Membranous nephropathy - crucial developments for diagnostic and treatment
    Stahl, R. A. K.
    Harendza, S.
    Helmchen, U.
    Hoxha, E.
    DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 2014, 139 (27) : 1433 - 1436
  • [10] COMMISSIONING THROUGH EVALUATION: RWE FOR RITUXIMAB IN THE MANAGEMENT OF IDIOPATHIC MEMBRANOUS NEPHROPATHY
    Patrick, H.
    Bui, K. H.
    Grzeda, M.
    Norton, S.
    Austin, C.
    Barnes, A.
    Kanigicherla, D.
    Khwaja, A.
    VALUE IN HEALTH, 2022, 25 (12) : S340 - S340